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OBJECTIVE—Extracellular nucleotides and nucleosides are
involved in regulation of skeletal muscle blood ﬂow. Diabetes
induces cardiovascular dysregulation, but the extent to which
the vasodilatatory capacity of nucleotides and nucleosides is
affected in type 2 diabetes is unknown. The present study
investigated 1) the vasodilatatory effect of ATP, uridine-triphos-
phate (UTP), and adenosine (ADO) and 2) the expression and
distribution of P2Y2 and P2X1 receptors in skeletal muscles of
diabetic subjects.
RESEARCH DESIGN AND METHODS—In 10 diabetic pa-
tients and 10 age-matched control subjects, leg blood ﬂow (LBF)
was measured during intrafemoral artery infusion of ATP, UTP,
and ADO, eliciting a blood ﬂow equal to knee-extensor exercise
at 12 W (2.6 l/min).
RESULTS—The vasodilatatory effect of the purinergic system
was 50% lower in the diabetic group as exempliﬁed by an LBF
increase of 274  37 vs. 143  26 ml/mol ATP  kg, 494  80
vs. 234  39 ml/mol UTP  kg, and 14.9  2.7 vs. 7.5  0.6
ml/mol ADO  kg in control and diabetic subjects, respectively,
thus making the vasodilator potency as follows: UTP control
subjects (100)  ATP control subjects (55)  UTP diabetic subjects
(47)  ATP diabetic subjects (29)  ADO control subjects (3) 
ADO diabetic subjects (1.5). The distribution and mRNA expression
of receptors were similar in the two groups.
CONCLUSIONS—The vasodilatatory effect of the purinergic
system is severely reduced in type 2 diabetic patients. The
potency of nucleotides varies with the following rank order:
UTP  ATP  ADO. This is not due to alterations in receptor
distribution and mRNA expression, but may be due to differences
in receptor sensitivity. Diabetes 59:182–189, 2010
T
he net balance between vasoconstrictor and
vasodilator activity in patients with type 2 dia-
betes is abnormal, and the ability of adjusting
vascular tone during conditions with increased
demands for blood ﬂow is affected (1,2). The level of
secretion and bioavailability of the potent vasodilators
nitric oxide (NO) and prostacyclin (prostaglandin [PG])
are diminished, and there is an increase in the synthesis,
secretion, and action of vasoconstrictors including prosta-
noids, angiotensin II, endothelin, and noradrenalin (3).
This leads to impaired vascular reactivity, which may limit
exercise capacity in patients with type 2 diabetes.
In the last decade, the purinergic system and its impact
on blood ﬂow regulation have come more into focus.
Several studies have shown that extracellular nucleotides
and nucleosides such as ATP, uridine-triphosphate (UTP),
and adenosine (ADO) are factors in the local control of
vessel tone (4) and regulation of exercise-induced hyper-
emia (5). Interestingly, reduced ATP release has been
shown in diabetic patients (6).
Whereas UTP and ADO are pure vasodilators, ATP
possesses the ability to induce both vasodilatation and
vasoconstriction; ATP-induced vasodilatation is assumed
to be a result of intravascular release of ATP from endo-
thelial cells or erythrocytes, leading to release of NO and
PG via endothelial purinergic receptors (7,8), whereas
extravascular ATP leads to vasoconstriction by direct
action on receptors on smooth muscle cells (9). Nucleo-
tides and nucleosides mediate a biological response via
two main categories of cell surface receptors: P1 receptor
for ADO and P2 receptor recognizing primarily ATP, UTP,
ADP, and uridine-diphosphate. P2 receptors are subdi-
vided into P2X and P2Y, based on their pharmacological
properties; P2Y is a family of G-protein–coupled recep-
tors, whereas P2X is a group of ligand-gated ion channel
receptors (10,11).
Attenuated function of purinergic receptors is impli-
cated in multiple diseases (12). The aim of the present
study was therefore to evaluate whether the endothelial
dysfunction in type 2 diabetic patients is associated with
impairment of the vascular sensitivity to extracellular
nucleotides and nucleosides. We hypothesized that puri-
nergic-mediated vasodilation is diminished in type 2 dia-
betic patients because of decreased receptor density
and/or sensitivity. We determined localization of P2Y2 and
P2X1 receptors and measured levels of mRNA of P2Y2
receptors to investigate potential downregulation.
RESEARCH DESIGN AND METHODS
Ten subjects with type 2 diabetes and 10 healthy subjects participated in the
study. All participants were fully informed of risks and discomforts associated
with the experiment before giving informed written consent. The study was
approved by the ethics committee in Copenhagen County and conducted in
accordance with the guidelines of the Declaration of Helsinki. The diabetic
patients were recruited from outpatient clinics and selected by World Health
Organization criteria (Table 1).
On the day of the experiment, the subjects arrived at the laboratory after
a light breakfast, refraining from alcohol and caffeine for 12 h. The diabetic
subjects maintained their usual antidiabetic treatment. Before the trials, BMI
and leg mass were calculated from whole-body dual-energy X-ray absorpti-
ometry scanning (Prodigy; GE Medical Systems, Waukesha, WI).
Experimental design. The subjects did a pretest of one-legged knee exten-
sion (2–4 min) at 12 W (200g and 60 rotations per min) to determine the
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182 DIABETES, VOL. 59, JANUARY 2010 diabetes.diabetesjournals.orgindividual rise in leg blood ﬂow (LBF) to this workload. The measured LBF
was the target ﬂow during the following infusions of nucleotides.
After the pretest, catheters were placed into the femoral artery and vein of
the experimental leg and into the femoral artery of the nonexperimental leg
under local anesthesia (5 g/ml lidocain; Region Hovedstadens Apotek). A
muscle biopsy was obtained from the middle portion of the vastus lateralis
muscle using the percutaneous needle biopsy technique with suction.
Endothelial function was described by the vasodilatatory response to
intra-arterial infusion of acetylcholine (10 mg/ml Miochol-E; Novartis). During
this test, the subjects were in a supine position to avoid an effect on cardiac
output as a result of reduced preload. An LBF response 1.5 l/min to 320
g/min (50% reduction compared with that in control subjects) was deﬁned
as endothelial dysfunction. One diabetic participant was excluded due to a
response higher than 1.5 l/min.
After 20 min of rest, the subjects were seated in the one-legged knee-
extensor ergometer. In random order, infusions of ATP (A7699; Sigma), UTP
(U6625; Sigma), and ADO (Item Development, Stocksund, Sweden) were
performed; all drugs were dissolved in isotonic saline and infused into the
femoral artery of the experimental leg. Infusion rates were increased until LBF
reached a steady state at the target LBF determined during the pretest, and the
infusion rate was maintained for 8 min. Ultimately, 8 min of one-legged
exercise at 12 W was performed. The subjects rested at least 20 min after each
intervention.
A scheduled test with nitroglycerin had to be renounced due to massive
side effects. The infusion rate required to obtain an LBF similar to the
exercise-induced LBF resulted in substantial decrease in mean arterial pres-
sure (MAP) and severe headache in the ﬁrst two subjects studied.
For the substances used, we titrated the amount needed to elicit an LBF
similar to LBF during exercise (Fig. 1).
Experimental techniques. LBF was measured with ultrasound Doppler
(Vivid 7; GE Healthcare) probe 8C. The two-dimensional frequency was 6.7
MHz and the pulsed wave frequency 5 MHz. During rest, the diameter of the
femoral artery was determined under a perpendicular insonation angle as an
average of three measurements (13). The site of blood velocity measurements
in the common femoral artery was distal to the inguinal ligament but above
the bifurcation into the superﬁcial and profound femoral branch to avoid
turbulence from the bifurcation. At this position, proximal to the exercising
muscles, the vessel diameter is unaffected by contraction and relaxation (13).
All recordings were obtained below an insonation angle of 60°. Sample volume
was placed in the center of the vessel, adjusted to the width of the diameter,
and kept clear of the vessel walls. Sample volume varied between 4.4 and 6.3
mm. Low-velocity ﬁlter (velocities 1.8 m/s) rejected noises caused by
turbulence at the vascular wall.
Blood velocity was measured at baseline and after 4 and 8 min of infusion
or exercise. Each time recording was obtained during three intervals of at
minimum eight heart cycles. The spectrum was autotraced to standardize the
calculations. LBF was calculated by multiplying the cross-sectional area of the
femoral artery with the amplitude, Vmean, and the three measurements were
averaged.
Heart rate was recorded with an electrocardiogram, and MAP was moni-
tored with transducers positioned at heart level (Pressure Monitoring Kit;
Baxter, Deerﬁeld, IL); data were continuously recorded using a powerlab
system (ADInstruments, Sydney, Australia).
Blood samples were collected at baseline and after 4 and 8 min of exercise
or infusion in steady state and at the target LBF. Blood samples were obtained
from the femoral artery of the nonexperimental leg and with a 5-s delay from
the femoral vein of the experimental leg. Blood gases and hemoglobin were
measured using an ABL725 analyzer (Radiometer, Copenhagen, Denmark).
Muscle biopsies were separated in two parts: one part was quickly frozen
in liquid nitrogen (15 s) and the other part was ﬁxed in Tissue-Tek (Sakura,
Torrance, CA) and carefully frozen in isopentane, placed in a cup in liquid
nitrogen. Both parts of the biopsies were stored at 80°C until they were
analyzed.
Quantiﬁcation of P2Y2 receptors. Total RNA was isolated from 20 mg of
muscle tissue by a modiﬁed guanidinium thiocyanate–phenol-chloroform
extraction method adapted from Chomczynski and Sacchi (1987) as previ-
ously described (14). Superscript II RNase H
 system (Invitrogen, Carlsbad,
CA) and oligodeoxythymidylic acids were used to reverse transcribe the
mRNA to cDNA. The cDNA samples were diluted in nuclease-free H2Ot oa
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FIG. 1. Scatter plots of LBF per micromole of infused ATP, UTP, and
ADO, respectively, normalized for leg total mass. Infusion rates were
carefully titrated to elicit an LBF, similar to LBF during exercise. E,
Control subjects; f, diabetic subjects.
TABLE 1
Demographic data for 10 healthy volunteers and 10 diabetic
patients
Control
subjects
Diabetic
patients
Male/female subjects (n) 7/3 7/3
Age (years) 51  25 3  3
Body weight (kg) 77  39 6  6*
BMI (kg/m
2) 24  13 0  1*
Total leg mass (kg) 14.4  0.5 15.8  0.8
Leg muscle mass (kg) 9.8  0.5 10.1  0.6
GHb (%) 7.8  0.5
Cholesterol (mmol/l) 4.7  0.3 4.3  0.6
HDL cholesterol (mmol/l) 1.7  0.2 1.4  0.3
LDL cholesterol (mmol/l) 2.7  0.2 2.5  0.5
Data are means  SE unless otherwise indicated. *P  0.01 different
from control.
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diabetes.diabetesjournals.org DIABETES, VOL. 59, JANUARY 2010 183total volume of 150 l. The amount of single-stranded DNA was determined in
each cDNA sample using OliGreen reagent (Molecular Probes, Leiden, the
Netherlands) as previously described (15).
The P2Y2 mRNA content was determined by PCR using the ﬂuorogenic 5
nuclease assay with TaqMan probes (ABI PRISM 7900 Sequence Detection
System; Applied Biosystems, Foster City, CA). Forward (5 CAGCACGGT
GCTCTGCAA 3) and reverse (5 CGCTGATGCAGGTGAGGAA 3) primers
and TaqMan probe (5 TGCGCTTCCTCTTCTACACCAACCTTTACTG 3) were
designed and optimized for the PCR (16). The obtained critical threshold
values reﬂecting the initial content of P2Y2 mRNA in the samples were
converted to an arbitrary amount using a standard curve obtained from a
serial dilution of a representative pooled sample. For each reverse transcrip-
tion sample, the amount of P2Y2 cDNA was normalized to the total cDNA
content.
Immunohistochemical analysis of P2Y2 and P2X1 receptors. The cellular
localizations were determined on 8-m transverse sections of frozen skeletal
muscle samples, incubated with a rabbit polyclonal 	 P2Y2 antibody (APR-010;
Alomone Laboratories, Jerusalem, Israel). Endothelial cells were detected
with a primary monoclonal antibody, mouse 	-CD31 (clone JC70A; DAKO,
Glostrup, Denmark) and smooth muscle cells with 	-smooth muscle cell actin
(m3558; DAKO) and then incubated with either biotin-coupled goat 	-rabbit
(E0432; DAKO) or biotin-coupled rabbit 	-mouse antibody (E0354; DAKO).
Staining of purinergic receptors, endothelial cells, and smooth muscle cells
was performed on serial sections. Antibody binding was visualized with
streptavidin coupled to ﬂuorescein isothiocyanate (FITC). Negative control
subjects were achieved without the primary antibody. Immunoreactive cells
were examined and photographed in a Zeiss Axioplan Microscope (Carl Zeiss,
Jena, Germany) (7).
Calculations. Cardiac output was calculated from arterial blood pressure
using the model ﬂow method (Beat Scope 1.1a; Finapress Medical Systems BV,
Amsterdam, the Netherlands). Stroke volume was calculated as the quotient
between cardiac output and heart rate. Leg vascular conductance (LVC) was
calculated as the quotient between LBF and MAP. Leg oxygen delivery was
calculated as the product of arterial oxygen content and LBF. Leg oxygen
uptake (VO2) was calculated as the product of the arterious-venous (a-v)
difference of oxygen and LBF.
Statistical analysis. Baseline values were tested using a Student t test.

-Values of the hemodynamic variables were analyzed by a two-way repeated-
measures ANOVA, with nucleotides and control/type 2 diabetes as between-
subject factors. If normality or equal variance failed, data were log-
transformed. There was no difference in any variable between 4 and 8 min of
infusion or exercise; therefore, only data after 8 min are presented. The
signiﬁcance level was set at P  0.05. Data are presented as means  SE
unless otherwise stated.
RESULTS
Flow responses and vasodilator potency. Both leg
muscle mass and leg total mass were comparable in
control versus diabetic subjects (Table 1). In addition, the
resting LBF was similar between the two groups (0.34 
0.02 vs. 0.27  0.03 l/min) (Fig. 2) as was the ﬂow response
to 12 W of workload (2.7  0.2 vs. 2.4  0.2 l/min).
However, the increase in LBF per micromole of infused
substance was different for control versus diabetic sub-
jects: 274  37 vs. 143  26 ml/mol ATP  kg, 494  80
vs. 234  39 ml/mol UTP  kg, and 15  3 vs. 7.5  0.6
ml/mol ADO  kg (Fig. 1). Thus, the vasodilator potency
was as follows: UTP control subjects (100)  ATP control
subjects (55)  UTP diabetic subjects (47)  ATP
diabetic subjects (29)  ADO control subjects (3)  ADO
diabetic subjects (1.5). Within the groups, the potency
varied with similar order of rank and proportions: UTP
(100)  ATP (55)  ADO (3) for control subjects versus UTP
(100)  ATP (61)  ADO (3.2) for the diabetic subjects.
Mean arterial pressure and leg vascular conductance.
MAP was similar in the two groups at baseline (109  6 vs.
99  4 mmHg for control subjects vs. diabetic subjects,
respectively) (Fig. 3). In both groups, MAP decreased
during all three infusions by 5–10 mmHg, with the largest
decrease during ATP infusion. During exercise, MAP in-
creased similarly (125  12 vs. 124  5 mmHg).
LVC was similar at baseline (3.0  0.2 vs. 2.7  0.3 ml 
min
1  mmHg
1 for control subjects vs. diabetic subjects,
respectively), during exercise (23  2 vs. 21  2), and
during the three infusions, increasing in the range of 26
to 30.
Oxygen delivery and uptake. Oxygen delivery to the leg
did not differ between the groups at baseline (59  6 vs.
49  4 ml/min) or during infusion or exercise (range
444–552 ml/min).
The a-v O2 difference was larger in the diabetic subjects
at baseline (78  5 vs. 100  6 ml/l). During the three
infusions, there were no differences in the groups, but
during exercise, a-v O2 difference was larger in the diabetic
group (129  4 vs. 142  6 ml/l).
The larger a-v difference in the diabetic group compen-
sated for a slightly lower LBF; both groups had a VO2 of
25 ml/min at baseline and 360 ml/min during exercise.
During the three infusions, VO2 ranged between 28 and 45
ml/min with no difference between the groups.
Venous lactate differed at baseline (1.0  0.2 vs. 2.0 
0.3 mmol/l), but there was no difference in the increase
during exercise (1.6 mmol/l) or in the decrease during
the infusions (0.1–0.3 mmol/l).
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FIG. 2. LBF responses showing that LBF was increased during infusions of ATP, UTP, and ADO to match LBF during exercise (Exe). The dose
needed to elicit the target LBF differed substantially. In the control group (left panel), the mean infusion rates were as follows: ATP, 0.8 mol/min
(range 0.4–1); UTP, 0.5 mol/min (range 0.2–1); and ADO, 13.7 mol/min (range 5–18). In the diabetic group (right panel), mean infusion rates
were as follows: ATP, 1.2 mol/min (range 0.5–2); UTP, 0.9 mol/min (range 0.5–2); and ADO, 19.4 mol/min (range 17–27).
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tended to be lower for the control group than the diabetic
group (67  3 vs. 77  4 bpm, P  0.056) (Fig. 4). Heart
rate increased by 5 bpm during infusions, independent of
group and nucleotide. During exercise, heart rate in-
creased to similar levels for the two groups (92  5 vs.
95  5 bpm for control subjects vs. diabetic subjects,
respectively).
Stroke volume was different at baseline (70  3 vs. 90 
5 ml/beat for control subjects vs. diabetic subjects, respec-
tively). The elevation of stroke volume during the infu-
sions was similar in the two groups and increased in the
range of 10–17 ml/min and was essentially unchanged
during exercise.
Consequently, cardiac output also differed at baseline
(4.7  0.2 vs. 6.8  0.5 l/min for control subjects vs.
diabetic subjects, respectively). There was, however, no
difference in the increase of cardiac output between the
two groups during the various interventions, although
the small increase in cardiac output during exercise
showed a tendency to be higher in the diabetic group
(P  0.056).
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FIG. 3. Local hemodynamic variables at baseline; during infusions of ATP, UTP, and ADO; and during exercise (Exer) in control (left panel) and
diabetic (right panel) subjects. *P < 0.05 compared with control subjects.
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P2Y2 and P2X1 receptors was identical in the two groups.
P2Y2 receptors were located in the endothelium of capil-
laries and in endothelium and smooth muscle cells of
microvessels. The P2X1 receptors were present in the
endothelium of capillaries and in the skeletal muscle
sarcolemma but not in smooth muscle cells (Fig. 5).
Also, the quantity of mRNA for P2Y2 receptors was
similar in the two groups (69  15 vs. 70  16 arbitrary
units for control subjects vs. type 2 diabetic subjects,
respectively).
DISCUSSION
The main ﬁndings of the present study are that 1) the
vasodilatatory response to ATP, UTP, and ADO infusion
was lower in patients with type 2 diabetes compared with
age-matched control subjects and 2) type 2 diabetes does
not affect the distribution or the gene expression of P2Y2
or P2X1 receptors.
Nucleotides have been found to play a role in the
regulation of skeletal muscle blood ﬂow during hyperemic
conditions, including exercise, where shear stress and
hypoxia are important stimuli of both ATP and UTP
release from endothelial cells. Erythrocytes are proposed
to function as oxygen sensors, contributing to the muscle
blood ﬂow regulation by the simultaneous release of ATP
and S-nitrosohemoglobin in proportion to off-loading O2
from the hemoglobin molecule, thereby inducing vasodi-
lation and a consequential rise in oxygen delivery to the
tissues in demand (17,18). However, erythrocytes from
humans with type 2 diabetes, incubated with the stimulat-
ing agent Mastoparan 7, released less ATP than erythro-
cytes from nondiabetic subjects (6). The vasodilatatory
effect of ATP, UTP, and ADO has so far been tested only in
young healthy subjects with a normal endothelial function.
In the current study, all diabetic subjects had endothelial
dysfunction as evidenced by a reduction in LBF during
acetylcholine infusion, and needed a higher dose of nucle-
otides, in general twice as much, to elicit a rise in leg blood
ﬂow similar to that achieved during moderate exercise.
These ﬁndings indicate that type 2 diabetes affects the
purinergic system, compromising cardiovascular regula-
tion in diabetic patients. It is, therefore, likely that the
reduced exercise capacity of diabetic patients is due partly
to less available ATP in combination with a reduction in
vasodilatatory potency of ATP.
The mechanisms underlying these ﬁndings may be sev-
eral. In young healthy subjects, pharmacological inhibition
of both NO and PG synthesis during ATP infusion has been
found to diminish leg blood ﬂow by 40%, indicating that
the vasodilatatory effect of ATP is mediated by NO and PG
but also by additional mechanisms (7). Similarly, inhibi-
tion of both NO and PG synthesis during ADO infusion has
been reported to reduce blood ﬂow by 70%, with a larger
reduction occurring during PG blockade compared with
NO blockade, suggesting that to a large extent, the vaso-
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FIG. 4. Systemic hemodynamic variables at baseline; during infusions of ATP, UTP, ADO; and during exercise (Exe) in control (left panel) and
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and that the increased NO formation could be prostaglan-
din mediated (19). Several studies show that type 2
diabetes diminishes the bioavailability of NO and PG and
decreases the half-life and activity of NO (20,21). Conse-
quently, part of the reduced vasodilatatory effect of the
infused nucleotides and nucleoside may be attributed to a
reduction in availability and activity of NO and/or prosta-
glandins or other mediators.
Alternatively, the impaired sensitivity to nucleotides
could be related to a more extensive formation and action
of vasoconstricting compounds. Diabetes is known to be
associated with increased synthesis of constrictory com-
pounds (i.e., prostanoids, endothelin, and angiotensin II);
therefore, a higher constrictory tone might underlie the
reduction in vasodilatatory effect of the purinergic ago-
nists (3,22). Also, type 2 diabetic patients have a higher
muscle sympathetic nerve activity and a higher sensitivity
to catecholamines (21,23). Enhanced adrenergic receptor
sensitivity might relate to endothelial damage because the
intact endothelium attenuates adrenergic reactivity in con-
trol arteries, a mechanism that was not present in arteries
from diabetic patients (24).
In contrast to NO, nucleotides are preferentially arterial
dilators. They are capable of regulating local vascular tone
in two complimentary ways. It was recently demonstrated
that ATP and UTP induce potent vasodilation at rest but
also oppose a concomitant increase in sympathetic activ-
ity as seen during exercise, indicating that circulating
nucleotides may be modulators of sympathetic vasocon-
striction during exercise—a phenomenon termed func-
tional sympatholysis (25–27). The phenomenon does not
occur during ADO or NO infusion or during NO blockade
during exercise, suggesting that other secondary metabo-
lites must be of importance (28).
Despite the reduced vasodilatatory capacity of ATP,
UTP, and ADO in the diabetic subjects, the response to
exercise was diminished by 10% in the diabetic group,
indicating that none of the infused substances is manda-
tory to elicit exercise hyperemia. Most exercise studies
show that blood ﬂow will be reduced but not hindered
despite multiple pathway blockades, suggesting that re-
dundancy will occur to sustain exercise performance. In
this context, ATP is not an obligatory vasodilator in
normal or pathological conditions and other systems may
be upregulated, exempliﬁed in settings of reduced NO
availability, for instance, in the endothelial nitric oxide
synthase knockout mice, where endothelium-derived hy-
perpolarizing factor–mediated relaxation in resistance ar-
teries is upregulated (29). Also, greater reliance on K-ATP
channels may occur (30).
In studies of young healthy subjects, ATP and UTP
showed the same potency in regulation of skeletal muscle
blood ﬂow. In contrast, ATP and UTP did not have equal
potency in the present study, either in the control or the
diabetic group. There are some possible explanations for
this. First, in vitro inhibition of NO-mediated dilatation of
ATP and UTP showed that UTP exceeded ATP, indicating
that UTP could be less dependent on NO (31). Moreover, a
recent study on the affect of aging on skeletal muscle
blood ﬂow found that age-dependent reduction in forearm
blood ﬂow is due to a decline in endothelial-derived NO
(32). Therefore, it is likely that a decrease in bioavailability
and activity of NO and PG affects the potency of ATP more
than the potency of UTP, leading to the differences ob-
served in the present study. Second, the intact endothe-
lium does not allow intraluminal ATP to pass the barrier
(33), but when endothelial damage occurs, it cannot be
excluded that intraluminal metabolites, including ATP,
diffuse to the interstitium, activating extraluminal P2X
receptors on vascular smooth muscle cells, thus resulting
in a concurrent vasoconstriction. UTP does not have this
constrictory ability, and endothelial leakage may, in this
context, affect the vasodilatatory effect of UTP less than
ATP. Also, regarding ADO, we found a change in potency
in both groups compared with that in other studies of
young healthy subjects (ATP:ADO  1:16 in young sub-
jects vs. 1:19 in both groups of the present study) (25).
Again, because the effect of ADO is mediated mainly by
formation of PG and NO, the impaired NO formation
accompanying aging may reduce the vasodilatatory effect
of ADO more than ATP and UTP, and the further reduction
of effect in the diabetic group reﬂects the supplementary
impact of diabetes on the mediators of the vasodilatatory
responses.
The present study focused on the peripheral aspects of
blood ﬂow and infusions were therefore performed in the
femoral artery with little effect on systemic hemodynamic
parameters. The diabetic subjects had higher stroke vol-
ume and cardiac output, but both variables are calculated,
and indirect measurements of cardiac output in obese
subjects may be overestimated. Importantly, there were no
P2X1
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Endo
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D C
E F
FIG. 5. Immunohistochemical localization of purinergic P2Y2 and P2X1
receptors in human skeletal muscle. A–D: Different staining on serial
sections. A: Positive staining for P2Y2 (APR-010; Alomone Laborato-
ries). B: Positive staining for endothelium (Endo) (ulex europaeus
agglutinin-1 [UEA-1]). C: Positive staining for vascular smooth muscle
cells (SMC) (-smooth muscle cell actin [m3558; DAKO]). D: Positive
staining for the P2X1 receptor (APR-001; Alomone Laboratories). P2Y2
purinergic receptors were present in endothelial cells of capillaries
and microvessels and in vascular smooth muscle cells, whereas P2X1
receptors were not present in smooth muscle cells. E and F: Positive
staining for the P2X1 receptor (APR-001; Alomone Laboratories) (E)
and positive staining for endothelium (ulex europaeus agglutinin-1)
(F) on the same section as in E. The P2X1 receptors were present in the
endothelium of capillaries and in the skeletal muscle sarcolemma.
Antibody binding was visualized with streptavidin coupled with FITC.
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-values. The trend of a slightly lower
LBF in the diabetic subjects during exercise may be the
result of a reduced exercise capacity because some dia-
betic subjects had difﬁculties fulﬁlling 8 min of exercise at
this modest workload despite the similar supply of
oxygen.
Quantiﬁcation of the P2Y2 receptor did not show differ-
ences in the level of gene expression in the two groups,
indicating that type 2 diabetes does not affect the rate and
way of mRNA expression of the P2Y2 receptor gene. This
does not preclude, however, that P2Y2 and P2X1 receptor
function could be altered in diabetic patients. It is well
known that pathology may induce differences in a tran-
scribed protein, thus modifying the properties of a protein
or a receptor after transcription. Immunohistochemical
analysis revealed that localization of P2Y2 and P2X1 recep-
tors was consistent with previous ﬁndings in young
healthy subjects, allowing us to conclude that the reduc-
tion in vasodilatatory potency is not due to changes in
receptor distribution. Still, the analysis is a qualitative
investigation and does not exclude differences in receptor
amount and a potential change in function of the recep-
tors; a profound morphological analysis of receptor
amount and quality could elucidate potential differences in
function and distribution of the receptors and target
proteins. P2X1 especially could be of interest because this
receptor is widely distributed in the plasma membrane of
skeletal muscle cells.
In summary, the present ﬁndings demonstrate that the
vasodilatatory potency of the purinergic system is attenu-
ated in diabetic patients and of such a magnitude that it
could be an important factor for the observed impairment
in regulation of vascular tone in diabetic patients. Poten-
tial explanations for the reduced effect of the purinergic
system could be 1) less available ATP as a result of a
decline in release from erythrocytes, 2) reduced bioavail-
ability of different mediators, 3) an intensiﬁed vasocon-
strictory counteraction, and 4) an increase in sympathetic
tone, resulting in impaired functional sympatholysis. The
present observations suggest that the purinergic system
may be involved in the pathogenesis of endothelial dys-
function and, thereby, underlie the cardiovascular compli-
cations associated with diabetes. The attenuation in
purinergic receptor responses could, in part, be implicated
in capillary rarefaction and impaired regulation of capil-
lary recruitment in skeletal muscle tissue, known to com-
promise insulin sensitivity and glucose uptake. The
current ﬁndings, in combination with existing evidence,
provide a basis for further studies addressing the mecha-
nisms underlying the reduced vascular function and exer-
cise capacity in diabetic patients.
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